Looking to bolster its planned Phase III trial with TP-434 (eravacycline) for complicated intra-abdominal infections, Tetraphase Pharmaceuticals Inc. filed for an initial public offering (IPO) that would raise up to $86.2 million, though neither the targeted number of shares nor the price of each was disclosed. Read More
NEW YORK – How does a biotech company look to set itself up as a potential acquisition target down the road? The answer, according to a panel at this year's BIO CEO & Investor Conference, is that it depends. Read More
StemCells Inc. reported positive results from the first patient cohort of a Phase I/II trial of its human neural stem cell product for spinal cord injury, and investors responded enthusiastically, driving the Newark, Calif.-based company's stock up 21 percent. Read More
Matthias Wymann, the Swiss scientist who discovered the first phosphoinositide 3-kinase (PI3K) inhibitor, is co-founder of a new cancer drug discovery start-up, Piqur Therapeutics AG, which recently completed a seed financing round that will enable it take forward a pipeline of next-generation kinase inhibitors. Read More
Lycera Corp. doubled its sweet 2011 deal with Merck and Co. Inc., of Whitehouse Station, N.J., in a new agreement designed to expand on the companies' prior relationship, which has centered on retinoic acid-related orphan receptor (ROR[gamma]t). Read More
• ImmunoGenes AG, of Zug, Switzerland, reported the incorporation of ImmunoGenes-ABS Zrt in Gödöllő, Hungary, as a fully owned subsidiary that will formalize the development and production of monoclonal and polyclonal antibodies for a commercial program called Customized Antibody Solutions. Read More
• Lorus Therapeutics Inc., of Toronto, said that biomarker data for its lead cancer therapy, LOR-253, will be presented in April at the 2013 annual meeting of the American Association for Cancer Research in Washington. Read More
• Dr. Reddy's Laboratories Ltd., of Hyderabad, India, declared its public offer to acquire the issued and outstanding shares of OctoPlus NV, of Leiden, the Netherlands, unconditional, with 37.2 million shares tendered during the offering period, representing 70.7 percent of shares. Read More
